Delcath Systems Stock News

The consensus price target hints at a 277.7% upside potential for Delcath Systems (DCTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings

Delcath Systems (DCTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.86 per share a year ago.

As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023's ups and downs; maybe not.

Is the stock market open on Thanksgiving? No, but that doesn't mean the shortened holiday week won't be packed with stock market moving catalysts.

Delcath's Hepzato Kit is the only liver directed FDA approved treatment for mUM, a rare form of cancer. It will launch in the US in January. The treatment had a 36.3% objective response rate, outperfo

Delcath Systems Inc. (NASDAQ:DCTH ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants David Hoffman - General Counsel, Chief Compliance Officer Gerard Michel - CEO San

NEW YORK , Nov. 6, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced tod

NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will partic

Delcath Systems (NASDAQ: DCTH ) stock is rocketing higher on Tuesday after getting an update from the FDA. This has the FDA approving HEPZATO KIT.

Delcath Systems recently passed FDA inspection without any manufacturing-related observations. The medical review for HEPZATO KIT has likely concluded successfully; FDA seems to have proposed a Black

NEW YORK , Aug. 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that

Delcath Systems is close to gaining FDA approval for its HEPZATO KIT, a minimally invasive liver cancer treatment. The company is well-funded and prepared for commercial operations in the U.S. and Eur

Delcath Systems Inc. (NASDAQ:DCTH ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Gerard Michel - Chief Executive Officer Anthony Dias - Vice President, Finance Kevin M

NEW YORK , May 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today